Skip to content

A randomized, double-blind, placebo-controlled, multi-center clinical trial of OsteoKing in the treatment of femoral shaft fracture (Qi stagnation and blood stasis syndrome)

A randomized, double-blind, placebo-controlled, multi-center clinical trial of OsteoKing in the treatment of femoral shaft fracture (Qi stagnation and blood stasis syndrome)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024738
Enrollment
Unknown
Registered
2019-07-26
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral shaft fracture (Qi stagnation and blood stasis syndrome)

Interventions

Sponsors

Beijing Jishuitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. patients with unilateral femoral shaft fracture received anterograde intramedullary needle internal fixation and successful closed reduction; 2. consistent with TCM syndrome differentiation and diagnosis of qi stagnation and blood stasis; 3. patients within 24 hours after surgery; 4. men aged 18 to 60 years old, women aged 18 to 50 years old; 5. after the researchers detailed the advantages and disadvantages of the study, the patients were willing to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. pathological fracture; 2. patients with soft tissue infection at the operation site; 3. patients with pain caused by other diseases; 4. combined with severe diseases of heart, lung, liver, kidney and hematopoietic system, ALT, AST > 2 times normal reference value upper limit, upper limit of Scr > normal reference value; 5. pregnancy, lactation or intended pregnancy, including male subjects who have fertility intention or family planning during the study period; 6. history of mental illness and glaucoma; 7. other drugs affecting the evaluation of disease efficacy, such as bisphosphonate, calcitonin, and stimulant, were used within 30 days prior to enrollment Vegetarian drugs, etc. 8. those who are known to be allergic to or allergic to the ingredients of this drug; 9. according to the judgment of the researcher, follow-up and compliance of the subjects may be affected after enrollment, such as out-of-town patients, unstable life, inconvenient traffic, etc. 10. patients enrolled in other clinical trials within 1 month.

Design outcomes

Primary

MeasureTime frame
VAS score for pain;Radiographic Union Score;

Secondary

MeasureTime frame
Fracture Healing Time;Swelling time;Pain time;Frequency and dosage of analgesics;TCM score;Single symptom of TCM;European five-dimensional health scale (eq-5d) score;Security Index;Pharmacoeconomic evaluation index;

Countries

China

Contacts

Public ContactWu Xinbao

Beijing Jishuitan Hospital

cuiyanzheng_2001@163.com+86 010-58516884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026